Infinimmune has raised $75m in Series A financing, helping the biotech advance its atopic dermatitis (AD)-centric pipeline.
As part of the round, Infinimmune garnered the interest of several major industry players, including Regeneron’s venture, which co-led the biotech’s raise with Playground Global, while MSD’s (Merck & Co) global health innovation fund participated alongside other life sciences investors.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Infinimmune already has a clear area in which it will spend the Series A tranche. While not disclosing how it will split the money, the biotech said the financing will accelerate clinical development of its two lead programmes in AD, as well as supporting additional programmes and advancing its Anthrobody discovery platform.
Infinimmune’s platform helps create longer-lasting antibodies while maintaining potency. It does this by screening millions of single memory B cells across hundreds of targets to identify natively paired, fully human antibodies. So far, the company has IFX-101 and IFX-201, monoclonal antibodies that target IL-22 and IL-13, respectively. First-in-human studies with the assets are slated to begin in 2027.
Wyatt McDonnell, co-founder and CEO of Infinimmune, said: “The human immune system makes extraordinary antibodies. We built a company to find them and are uniquely positioned to turn them into transformative medicines for patients with unmet needs. This financing enables Infinimmune to bring that promise to the clinic, as we work alongside a world-class syndicate to develop the molecules that patients living with inflammatory diseases deserve.”
For Regeneron, contributing to Infinimmune’s development means it is advancing a potential rival to Dupixent (dupilumab), the blockbuster anti-inflammatory injection that has dominated the AD landscape for years.
Dupixent, co-marketed with Sanofi, targets both IL-4 and IL-13, meaning there is some overlap with Infinimmune’s pathway targets. The patents for Dupixent, which generated $17.8bn in sales in 2025, are set to expire around 2031. Regeneron and Sanofi are already building out their pipelines to preserve their dominance in the AD market, though assets like those being developed by Infinimmune could provide future bolt-on options.
Infinimmune is targeting a crowded yet lucrative market. GlobalData forecasts that AD across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) will be worth $22.4bn in 2033. GlobalData is the parent company of Pharmaceutical Technology.
MSD, meanwhile, is already familiar with Infinimmune. In March 2026, Infinimmune signed a multi-target antibody discovery collaboration with the big pharma company that includes up to approximately $838m in upfront and potential milestone payments.
